| NDC-11 (Package) | NDC-9 (Product) | Generic Name | Brand Name | Strength | SEER*Rx Category | Major Class | Minor Class | Administration Route | Package Effective Date | Package Discontinuation Date | Status |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 62756-0239-20 | 62756-0239 | Capecitabine | Capecitabine | 500.0 mg/1 | Chemotherapy | Antimetabolite | Pyrimidine Analog | Oral | Sep 1, 2019 | In Use | |
| 69539-0319-05 | 69539-0319 | Abiraterone acetate | Abiraterone | 500.0 mg/1 | Hormonal Therapy | Androgen Receptor Inhibitor | CYP17 Inhibitor | Oral | Apr 26, 2024 | In Use | |
| 00179-0149-70 | 00179-0149 | Capecitabine | Capecitabine | 500.0 mg/1 | Chemotherapy | Antimetabolite | Pyrimidine Analog | Oral | May 14, 2014 | Mar 31, 2016 | In Use |
| 69539-0020-92 | 69539-0020 | Capecitabine | Capecitabine | 500.0 mg/1 | Chemotherapy | Antimetabolite | Pyrimidine Analog | Oral | Jul 2, 2018 | In Use | |
| 55111-0497-04 | 55111-0497 | capecitabine | capecitabine | 500.0 mg/1 | Chemotherapy | Antimetabolite | Pyrimidine Analog | Oral | Dec 10, 2020 | In Use | |
| 55150-0264-20 | 55150-0264 | Methylprednisolone Sodium Succinate | Methylprednisolone Sodium Succinate | 500.0 mg/1 | Hormonal Therapy | Adrenal Glucocorticoid | Corticosteroid | Intramuscular, Intravenous | Dec 15, 2015 | In Use | |
| 59923-0722-12 | 59923-0722 | Capecitabine | Capecitabine | 500.0 mg/1 | Chemotherapy | Antimetabolite | Pyrimidine Analog | Oral | Mar 1, 2020 | In Use | |
| 31722-0775-12 | 31722-0775 | Capecitabine | Capecitabine | 500.0 mg/1 | Chemotherapy | Antimetabolite | Pyrimidine Analog | Oral | Mar 5, 2024 | In Use | |
| 54868-4773-03 | 54868-4773 | Hydroxyurea | Hydroxyurea | 500.0 mg/1 | Chemotherapy | Miscellaneous Agent | Antimetabolite/Organooxygen | Oral | Apr 11, 2003 | In Use | |
| 65162-0844-16 | 65162-0844 | Capecitabine | Capecitabine | 500.0 mg/1 | Chemotherapy | Antimetabolite | Pyrimidine Analog | Oral | Mar 10, 2017 | Feb 1, 2024 | No Longer Used |
| 55154-7143-00 | 55154-7143 | Hydroxyurea | Hydroxyurea | 500.0 mg/1 | Chemotherapy | Miscellaneous Agent | Antimetabolite/Organooxygen | Oral | Aug 12, 2008 | Sep 30, 2024 | No Longer Used |
| 69539-0319-60 | 69539-0319 | Abiraterone acetate | Abiraterone | 500.0 mg/1 | Hormonal Therapy | Androgen Receptor Inhibitor | CYP17 Inhibitor | Oral | Apr 26, 2024 | In Use | |
| 31722-0775-60 | 31722-0775 | Capecitabine | Capecitabine | 500.0 mg/1 | Chemotherapy | Antimetabolite | Pyrimidine Analog | Oral | Apr 19, 2024 | In Use | |
| 69097-0948-08 | 69097-0948 | Capecitabine | Capecitabine | 500.0 mg/1 | Chemotherapy | Antimetabolite | Pyrimidine Analog | Oral | Jul 1, 2023 | In Use | |
| 63629-9430-01 | 63629-9430 | Abiraterone acetate | Abiraterone Acetate | 500.0 mg/1 | Hormonal Therapy | Androgen Receptor Inhibitor | CYP17 Inhibitor | Oral | Aug 23, 2022 | In Use | |
| 60505-4764-06 | 60505-4764 | Abiraterone acetate | Abiraterone acetate | 500.0 mg/1 | Hormonal Therapy | Androgen Receptor Inhibitor | CYP17 Inhibitor | Oral | Jul 16, 2021 | In Use | |
| 69539-0020-99 | 69539-0020 | Capecitabine | Capecitabine | 500.0 mg/1 | Chemotherapy | Antimetabolite | Pyrimidine Analog | Oral | Jul 2, 2018 | In Use | |
| 42291-0167-12 | 42291-0167 | Capecitabine | Capecitabine | 500.0 mg/1 | Chemotherapy | Antimetabolite | Pyrimidine Analog | Oral | Apr 14, 2017 | May 31, 2020 | In Use |
| 54868-4773-02 | 54868-4773 | Hydroxyurea | Hydroxyurea | 500.0 mg/1 | Chemotherapy | Miscellaneous Agent | Antimetabolite/Organooxygen | Oral | Apr 11, 2003 | In Use | |
| 62135-0784-12 | 62135-0784 | Capecitabine | Capecitabine | 500.0 mg/1 | Chemotherapy | Antimetabolite | Pyrimidine Analog | Oral | Oct 16, 2023 | In Use | |
| 68001-0488-07 | 68001-0488 | CAPECITABINE | CAPECITABINE | 500.0 mg/1 | Chemotherapy | Antimetabolite | Pyrimidine Analog | Oral | Feb 22, 2021 | In Use | |
| 70518-3615-00 | 70518-3615 | HYDROXYUREA | HYDROXYUREA | 500.0 mg/1 | Chemotherapy | Miscellaneous Agent | Antimetabolite/Organooxygen | Oral | Jan 10, 2023 | In Use | |
| 00069-0136-01 | 00069-0136 | Bosutinib monohydrate, Bosutinib | Bosulif | 500.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | BCR-ABL | Oral | Sep 4, 2012 | In Use | |
| 62756-0239-83 | 62756-0239 | Capecitabine | Capecitabine | 500.0 mg/1 | Chemotherapy | Antimetabolite | Pyrimidine Analog | Oral | Sep 1, 2019 | In Use | |
| 66220-0110-01 | 66220-0110 | Dexrazoxane Hydrochloride | Totect | 500.0 mg/1 | Ancillary Therapy | Chemoprotective | Detoxifying Agent | Intravenous | Jul 25, 2017 | Oct 30, 2020 | No Longer Used |
Found 12159 results — Export these results
Home